Does Gilenya (fingolimod) cause side effects?
Its mechanism of action is unknown, although it may work by reducing the number of circulating lymphocytes (a type of white blood cell), leading to reduced migration of white blood cells into the central nervous system.
White blood cells cause inflammation and destruction of nerves in patients with MS. Gilenya does not cure MS. It decreases the number of MS flares and slows down the development of physical disability caused by MS.
Common side effects of Gilenya include
Gilenya may decrease heart rate, especially after the first dose.
Serious side effects of Gilenya include
- increased risk of infections,
- inflammation of the eye (uveitis) and other eye problems,
- difficulty breathing, and
- reduced white blood cell count.
- Vaccines may be less effective during and up to 2 months after discontinuation of Gilenya treatment.
- Live attenuated vaccines should not be administered during and for 2 months after Gilenya treatment because of the risk of infection.
- When combined with drugs that decrease heart rate (for example, atenolol) there is an additional 15% reduction of heart rate.
What are the important side effects of Gilenya (fingolimod)?
The most common side effects are:
Fingolimod may decrease heart rate, especially after the first dose. Patients should be observed for signs and symptoms of low heart rate for 6 hours after the first dose.
Fingolimod may increase the risk of infections. Signs and symptoms of infection should be monitored during treatment and for two months after discontinuation of treatment. Fingolimod should not be administered to patients who have an infection.
Fingolimod may cause inflammation of the eye (uveitis) and other eye problems. Therefore, visual acuity should be checked prior to starting therapy, 3 to 4 months after initiation of therapy, and during routine patient evaluation.
Fingolimod has also been associated with difficulty breathing. Fingolimod reduces the white blood cell count, and this effect may last for 2 months after treatment is discontinued.
Gilenya (fingolimod) side effects list for healthcare professionals
The following serious adverse reactions are described elsewhere in labeling:
- Bradyarrhythmia and Atrioventricular Blocks
- Progressive Multifocal Leukoencephalopathy
- Macular Edema
- Liver Injury
- Posterior Reversible Encephalopathy Syndrome
- Respiratory Effects
- Fetal Risk
- Severe Increase in Disability After Stopping Gilenya
- Increased Blood Pressure
- Immune System Effects Following Gilenya Discontinuation
- Hypersensitivity Reactions
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical trials (Studies 1, 2, and 3), a total of 1212 patients with relapsing forms of multiple sclerosis received Gilenya 0.5 mg. This included 783 patients who received Gilenya 0.5 mg in the 2-year placebo-controlled trials (Studies 1 and 3) and 429 patients who received Gilenya 0.5 mg in the 1-year active-controlled trial (Study 2).
The overall exposure in the controlled trials was equivalent to 1716 person-years. Approximately 1000 patients received at least 2 years of treatment with Gilenya 0.5 mg. In all clinical studies, including uncontrolled extension studies, the exposure to Gilenya 0.5 mg was approximately 4119 person-years.
In placebo-controlled trials, the most frequent adverse reactions (incidence ≥ 10% and greater than placebo) for Gilenya 0.5 mg were
- liver transaminase elevation,
- back pain,
- abdominal pain, and
- pain in extremity.
Adverse events that led to treatment discontinuation and occurred in more than 1% of patients taking Gilenya 0.5 mg were serum transaminase elevations (4.7% compared to 1% on placebo) and basal cell carcinoma (1% compared to 0.5% on placebo).
Table 1 lists adverse reactions in clinical studies in adults that occurred in ≥ 1% of Gilenya-treated patients and ≥ 1% higher rate than for placebo.
Table 1: Adverse Reactions Reported in Adult Studies 1
and 3 (Occurring in ≥ 1% of Patients and Reported for Gilenya 0.5 mg at
≥ 1% Higher Rate than for Placebo)
|Adverse Drug Reactions||Gilenya 0.5 mg
N = 783 %
N = 773 %
|Tinea versicolor||2||< 1|
|Nervous system disorders|
|General disorders and administration site conditions|
|Musculoskeletal and connective tissue disorders|
|Pain in extremity||10||7|
|Skin and subcutaneous tissue disorders|
|Liver transaminase elevations (ALT/GGT/AST)||15||4|
|Blood triglycerides increased||3||1|
|Respiratory, thoracic, and mediastinal disorders|
|Blood and lymphatic system disorders|
|Neoplasms benign, malignant and unspecified (including cysts and polyps)|
|Basal cell carcinoma||2||1|
Adverse reactions of seizure, dizziness, pneumonia, eczema, and pruritus were also reported in Studies 1 and 3, but did not meet the reporting rate criteria for inclusion in Table 1 (difference was less than 1%).
Adverse reactions with Gilenya 0.5 mg in Study 2, the 1-year active-controlled (versus interferon beta-1a) study were generally similar to those in Studies 1 and 3.
- Vascular events, including ischemic and hemorrhagic strokes, and peripheral arterial occlusive disease were reported in premarketing clinical trials in patients who received Gilenya doses (1.25-5 mg) higher than recommended for use in MS.
- Similar events have been reported with Gilenya in the postmarketing setting although a causal relationship has not been established.
- Cases of seizures, including status epilepticus, have been reported with the use of Gilenya in clinical trials and in the postmarketing setting in adults.
- In adult clinical trials, the rate of seizures was 0.9% in Gilenya-treated patients and 0.3% in placebo-treated patients.
- It is unknown whether these events were related to the effects of multiple sclerosis alone, to Gilenya, or to a combination of both.
Pediatric Patients 10 Years Of Age And Older
- In the controlled pediatric trial (Study 4), the safety profile in pediatric patients receiving Gilenya 0.25 mg or 0.5 mg daily was similar to that seen in adult patients.
- In the pediatric study, cases of seizures were reported in 5.6% of Gilenya-treated patients and 0.9% of interferon beta-1a-treated patients.
The following adverse reactions have been identified during postapproval use of Gilenya. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Hepatobiliary Disorders: Liver injury
- Infections: infections including cryptococcal infections, progressive multifocal leukoencephalopathy
- Musculoskeletal and connective tissue disorders: arthralgia, myalgia
- Nervous system disorders: posterior reversible encephalopathy syndrome, seizures, including status epilepticus
- Neoplasms, benign, malignant, and unspecified (incl cysts and polyps): melanoma, Merkel cell carcinoma, and cutaneous T cell lymphoma (including mycosis fungoides)
- Skin and subcutaneous tissue disorders: hypersensitivity
What drugs interact with Gilenya (fingolimod)?
QT Prolonging Drugs
- Gilenya has not been studied in patients treated with drugs that prolong the QT interval.
- Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia.
- Since initiation of Gilenya treatment results in decreased heart rate and may prolong the QT interval, patients on QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility.
- The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole.
- Patients who use Gilenya and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.
- Gilenya reduces the immune response to vaccination. Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with Gilenya.
- Avoid the use of live attenuated vaccines during and for 2 months after treatment with Gilenya because of the risk of infection.
- It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Gilenya therapy.
Antineoplastic, Immunosuppressive, Or Immune-Modulating Therapies
- Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with Gilenya.
- When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating Gilenya.
Drugs That Slow Heart Rate Or Atrioventricular Conduction (e.g., beta blockers or diltiazem)
- Experience with Gilenya in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited.
- Because initiation of Gilenya treatment may result in an additional decrease in heart rate, concomitant use of these drugs during Gilenya initiation may be associated with severe bradycardia or heart block.
- Seek advice from the physician prescribing these drugs regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating Gilenya.
- Patients who cannot switch should have overnight continuous ECG monitoring after the first dose.
Laboratory Test Interaction
- Because Gilenya reduces blood lymphocyte counts via redistribution in secondary lymphoid organs, peripheral blood lymphocyte counts cannot be utilized to evaluate the lymphocyte subset status of a patient treated with Gilenya.
- A recent CBC should be available before initiating treatment with Gilenya.
Gilenya (fingolimod) is a sphingosine 1-phosphate receptor modulator used to treat multiple sclerosis (MS). Common side effects of Gilenya include headache, flu, diarrhea, back pain, elevations of liver enzymes and cough. Gilenya may decrease heart rate, especially after the first dose. Gilenya has not been adequately studied in pregnant women. It is unknown if Gilenya is secreted in breast milk.
Multimedia: Slideshows, Images & Quizzes
Multiple Sclerosis (MS) Quiz: Test Your Medical IQ
Multiple Sclerosis is a debilitating neurological condition. Take the MS Quiz to test your knowledge of the causes, symptoms,...
Picture of Multiple Sclerosis Symptoms
Symptoms of multiple sclerosis may be single or multiple and may range from mild to severe in intensity and short to long in...
What Is Multiple Sclerosis? MS Symptoms, Causes, Diagnosis
MS is an autoimmune disease that attacks the nerves of the central nervous system. Learn about multiple sclerosis (MS) causes,...
What You Should Know About Multiple Sclerosis
Learn about celebrities, such as Montel Williams and Jack Osbourne, who are living with multiple sclerosis.
Multiple Sclerosis: Making an MS Friendly Home
Adults with multiple sclerosis may be at risk for injuries, hazards, and falling at home. Some simple home modifications can...
Related Disease Conditions
Multiple Sclerosis (MS) Symptoms, Causes, Treatment, Life Expectancy
Multiple sclerosis or MS is an autoimmune disorder in which brain and spinal cord nerve cells become demyelinated. This damage results in symptoms that may include numbness, weakness, vertigo, paralysis, and involuntary muscle contractions. Different forms of MS can follow variable courses from relatively benign to life-threatening. MS is treated with disease-modifying therapies. Some MS symptoms can be treated with medications.
Alternative Treatment for MS (CAM for MS)
The term alternative therapy, in general, is used to describe any medical treatment or intervention that has not been scientifically documented or identified as safe or effective for a specific condition. Alternative therapy encompasses a variety of disciplines that range from diet and exercise to mental conditioning to lifestyle changes.
Multiple Sclerosis (MS)
Multiple sclerosis (MS) symptoms vary from person to person, and can last for days to months without periods of remission. Symptoms of MS include sexual problems and problems with the bowel, bladder, eyes, muscles, speech, swallowing, brain, and nervous system. The early symptoms and signs of multiple sclerosis usually start between age 20 and 40. MS in children, teens, and those over age 40 is rare. Treatment options for multiple sclerosis vary depending on the type and severity of symptoms. Medications may be prescribed to manage MS symptoms.
Is MS Contagious? (Multiple Sclerosis)
Multiple sclerosis, or MS, is a degenerative disease of the covering around the nerves in the central nervous system (CNS). Researchers and doctors don't know the exact cause, but many theorize that it may be due to environmental triggers, an autoimmune disease, and viruses (infections). Symptoms of MS include vision changes, paralysis, vertigo, heat intolerance, slurred speech, sexual dysfunction, and urinary incontinence (the inability to urinate). There's no vaccine or cure for MS, but the progression and symptoms of the disease can be treated.
MS (Multiple Sclerosis) vs. ALS (Amyotrophic Lateral Sclerosis) Differences and Similarities
ALS (amyotrophic lateral sclerosis, Lou Gehrig's disease) and MS (multiple sclerosis) are both diseases of the nervous system (neurodegenerative). ALS is a disease in which the nerve cells in the body are attacked by the immune system, although it's not considered an autoimmune disease by some scientists. MS is an autoimmune disease in which the insulated covering of the nerves (myelin sheath) in the CNS (central nervous system) degenerate, or deteriorate. Scientists don't know the exact cause of either problem. However, they have discovered that mutations in the gene that produces the SOD1 enzyme were associated with some cases of familial ALS. Scientists also theorize that multiple sclerosis may be caused by infection or vitamin D deficiency. ALS occurs between 50-70 years of age (the average age of occurrence ALS is 55), and mostly affects men. While MS occurs between 20-60 years of age, and mostly affects women. About 30,000 people in the US have ALS, and an average of 5,000 new diagnoses per year (that's about 15 new cases per week). Worldwide, MS affects more than 2.3 million people, with about 10,000 new cases diagnosed each year (that's about 200 new diagnoses per week).Some of the signs and symptoms of both diseases include muscle weakness, muscle spasms, problems walking, fatigue, slurred speech, and problems swallowing. ALS signs and symptoms that are different from MS include problems holding the head upright, clumsiness, muscle cramps and twitches, problems holding objects, and uncontrollable periods of laughing or crying. MS signs and symptoms that are different from ALS include vision problems, vertigo and balance problems, sexual problems, memory problems, depression, mood swings, and digestive problems. There is no cure for either disease, however the prognosis and life expectancy are different. Multiple sclerosis is not a fatal condition, while ALS progresses rapidly and leads to death.
Multiple Sclerosis (MS) and Pregnancy
Multiple sclerosis or MS is a central nervous system disease in which the immune system attacks the myelin sheath (the protective coating around nerves). Symptoms of MS include pain, sexual problems, fatigue, numbness and tingling, emotional changes, and depression.Women who are pregnant and have multiple sclerosis may have more difficulty carrying a pregnancy. Multiple sclerosis does not affect ability to conceive, and does not seem to affect fertility. MS symptoms during pregnancy may stay the same or get better; however, they may worsen after giving birth. Pregnancy decreases the number of relapses, but flares increase in the first 3-6 months after delivery. Pregnant women with MS may carrying a pregnancy more difficult to tell when labor starts, and there is an increased need to use forceps or vacuum to assist with delivery or b7 C-section (Cesarean birth) increases. Some treatment MS drugs may be safe to use during pregnancy; however, some drugs should not be taken, for example, baclofen (Gablofen, Lioresal), fluoxetine (Prozac, Sarafem), or solifenacin succinate (VESIcare), and most disease-modifying therapies (DMTs). Talk with your healthcare team about vitamins, supplements, and medications that you are taking if you are pregnant and have MS.
Multiple Sclerosis (MS) Early Warning Signs and Types
Multiple sclerosis (MS) can be thought of as an immune-mediated inflammatory process involving different areas of the central nervous system (CNS) at various points in time. Early warning signs and symptoms of MS in children, teens, and adults are similar; however, children and teens with pediatric also may have seizures and a complete lack of energy. Adults with MS do not have these signs and symptoms. Other signs and symptoms of MS include inflammation of the optic nerve (optic neuritis), changes in vision, Wiping or having tissues around the eye and moving the eye may be painful, and double vision. There are four types of MS, relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), and progressive relapsing MD (PRMS).
Can Stress Cause Multiple Sclerosis (MS)?
Multiple sclerosis (MS) results when your immune system attacks the cells of the brain and spinal cord. It is an autoimmune disease, a condition in which the body’s immune system is misdirected and attacks its own cells. Stress can make it difficult for a person to manage MS symptoms. Regular exercise and mindful eating have been found to control the stress levels and overall health of people with MS.
What Are the Very First Signs of Multiple Sclerosis?
Multiple sclerosis (MS) is an inflammatory, neurodegenerative, and autoimmune disease that affects the brain and spinal cord of the central nervous system (CNS). MS is one of the most common causes of non-injurious disability in young and middle-aged adults.
What Are the Early Signs of Multiple Sclerosis?
Multiple sclerosis is an autoimmune disease in which the immune system attacks the central nervous system (spinal cord and brain) by damaging and destroying the protective myelin sheath around the nerve fibers. Someone with multiple sclerosis might develop problems with muscle control, vision, bladder control and other body functions.
Treatment & Diagnosis
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.